Viome Pricing History and Trajectory: What You Actually Pay Over Time

How Viome's Prices Have Moved Since 2018

Viome launched its first consumer gut microbiome test in 2018 at approximately $149 per kit. That price positioned it as a premium but accessible alternative to general wellness panels. Within two years, the company rebranded its core offering and raised the entry price.

By 2020, the "Gut Intelligence Test" sat at $179. A 2021 rebundle introduced the "Health Intelligence Test" at $249, pairing gut RNA sequencing with blood biomarkers. The current "Full Body Intelligence Test," released in 2022 and repriced in 2023, retails at $399 before any promotional discount. That is a 168% nominal price increase over six years.

Year-by-Year Price Milestones

| Year | Product Name | Listed Price | |------|-------------|-------------| | 2018 | Gut Intelligence Test (v1) | ~$149 | | 2020 | Gut Intelligence Test (v2) | $179 | | 2021 | Health Intelligence Test | $249 | | 2022 | Full Body Intelligence Test (launch) | $299 | | 2023 | Full Body Intelligence Test (reprice) | $349 | | 2024 | Full Body Intelligence Test (current) | $399 |

Price comparisons for competing direct-to-consumer microbiome tests show a divergent pattern. Ombre (formerly Thryve) held its single-test price near $99 through 2023. Genova Diagnostics' GI Effects panel, ordered through a licensed clinician, runs $400, $500 but includes a physician interpretation layer and CLIA-certified laboratory processing. The difference matters because CLIA certification sets minimum quality standards for clinical laboratory testing under federal law. [1]

What Drives the Price Trajectory

Three factors explain the upward trend. First, Viome transitioned from 16S rRNA sequencing (standard, lower cost) to metatranscriptomic RNA sequencing, which captures active gene expression in gut microbes rather than just microbial presence. The RNA approach is more technically demanding and does carry higher per-sample reagent costs. [2]

Second, Viome added oral microbiome sampling and blood biomarker panels to bundle justification. Third, and most commercially significant, the company shifted its revenue model toward recurring supplement subscriptions, making the test itself partly a customer-acquisition cost.

The Real Cost: Subscriptions and Supplements

The test price is not the total cost. Viome's business model depends on selling personalized supplement packs based on test results. These are manufactured by Viome and are not available from third-party retailers.

Supplement Pricing Structure

As of early 2025, Viome's precision supplement subscriptions run:

• Precision Probiotics: $50, $60/month
• Precision Prebiotics: $45, $55/month
• Full-stack personalized pack: $90, $120/month depending on formulation tier

A customer who tests once and follows the full supplement recommendation for 12 months spends $1,080, $1,440 on supplements alone, plus the $399 test fee. Total first-year outlay: approximately $1,479, $1,839.

Viome reprices supplements periodically without email notice beyond a routine order confirmation. Several Better Business Bureau complaints (BBB complaint ID records publicly accessible at bbb.org) describe unexpected charge increases on auto-ship orders. [3]

Auto-Ship Cancellation Problems

Auto-ship cancellation is one of the most common friction points in DTC supplement companies broadly, and Viome is not an exception. The FTC's 2023 "Click to Cancel" rule update, finalized under 16 CFR Part 425, requires that cancellation be as easy as enrollment for negative-option subscriptions. [4] Viome's cancellation flow as of 2024 still requires a phone or chat interaction rather than a single online toggle, which may place it in tension with this rule.

Documented Trustpilot reviews (aggregate rating 2.8/5.0 as of December 2024, N=approximately 1,200 reviews) cite charges continuing after cancellation requests as the most common complaint category.

Is Viome Legit? Regulatory and Scientific Standing

"Legit" has two separate dimensions here: commercial legitimacy (is it a real company that ships real products?) and clinical legitimacy (do the tests and recommendations rest on validated science?). The answers differ.

Commercial Legitimacy

Viome Life Sciences, Inc. Is a registered Delaware corporation headquartered in Bellevue, Washington. The company has raised over $170 million in venture funding across multiple rounds, including a $86.5 million Series C in 2020. It operates a CLIA-certified laboratory in Bothell, Washington, for the RNA sequencing component of its tests. CLIA certification means the lab meets federal proficiency and quality standards, which is a meaningful baseline. [1]

The company is not BBB-accredited as of January 2025, though it maintains a BBB profile with a B rating. Non-accreditation is not disqualifying by itself, but it means Viome has not committed to the BBB's standards of trust, including binding arbitration for unresolved complaints. [3]

LegitScript, which certifies online pharmacies and health platforms for compliance with applicable laws, does not list Viome as a certified entity. [5] This is relevant if you are evaluating Viome through the lens of regulated healthcare rather than wellness retail.

Clinical and Scientific Legitimacy

This is where independent scrutiny matters most. Viome's core claim is that metatranscriptomic profiling of gut microbiota can generate actionable, personalized dietary and supplement recommendations that improve health outcomes. That claim requires randomized controlled trial evidence to be considered clinically validated.

The human gut microbiome is genuinely complex and its relationship to systemic health is an active research area. A 2019 Cell paper (Sonnenburg and Sonnenburg, Stanford) demonstrated inter-individual variation in glycemic response to identical foods partly mediated by microbiome composition. [6] A 2022 Cell study from the Sonnenburg lab (N=36) found high-fiber diets increased microbiome diversity and reduced inflammatory markers. [7] These are real findings. They do not, however, validate any specific commercial testing algorithm or supplement protocol.

The FDA does not regulate dietary supplements for efficacy before sale. [8] Viome's supplement recommendations therefore carry no pre-market efficacy validation. The company has published one peer-reviewed study (Precept Medical, 2020) showing correlation between its metatranscriptomic scores and self-reported wellness outcomes, but correlation in an observational design is not causation. No phase III randomized controlled trial of Viome's full protocol (test plus supplements) has been published in a peer-reviewed journal indexed on PubMed as of this writing.

The NIH Human Microbiome Project established that microbiome composition varies substantially day to day within the same individual, influenced by recent diet, antibiotic use, and stress. [9] A single stool sample, as used by Viome, therefore captures a snapshot that may not reflect stable baseline microbiome state.

FDA Regulatory Status of the Test Itself

Viome markets its test as a wellness product, not a medical device, which allows it to avoid FDA 510(k) premarket notification requirements. The FDA's digital health and laboratory-developed test oversight framework has been evolving, but as of 2024, direct-to-consumer microbiome tests sold purely for wellness purposes are not required to demonstrate analytical or clinical validity before reaching consumers. [8]

The FDA issued warning letters to several DTC genetic and microbiome testing companies between 2019 and 2023 for making disease-specific claims that crossed into medical device territory. Viome has not received a public warning letter as of January 2025. The company appears to have calibrated its language to stay in wellness framing rather than diagnostic framing, though the line between "your microbiome suggests inflammation risk" and a disease claim is narrow. [8]

Evaluating Viome Against Clinical Microbiome Testing Standards

The table below contrasts Viome's testing model against the criteria clinicians use when ordering laboratory tests for patient care.

| Criterion | Clinical Standard | Viome's Status | |-----------|------------------|----------------| | CLIA-certified lab | Required for clinical tests | Yes | | Analytical validity (test measures what it claims) | Peer-reviewed validation | Partial; RNA sequencing methodology published | | Clinical validity (score predicts outcome) | RCT or prospective cohort | Not established by independent RCT | | Clinical utility (changes management, improves outcome) | Required for guideline adoption | Not established | | Physician order required | Yes for most clinical labs | No; DTC model | | FDA clearance/approval | Required for IVD medical devices | Not applicable (wellness framing) |

The American Gastroenterological Association's 2020 clinical practice update on the gut microbiome concluded: "The field is not yet at a stage where microbiome testing can be recommended to guide clinical decisions in most patients." [10] Viome's consumer-facing materials do not prominently feature this context.

What Metatranscriptomics Actually Measures

Viome's RNA sequencing method is technically more informative than standard 16S rRNA amplicon sequencing in that it captures which microbial genes are being actively expressed, not merely which organisms are present. A 2021 Nature Methods comparison found metatranscriptomic approaches identified functional activity patterns that 16S sequencing missed. [2] This is a legitimate methodological advantage. Whether that additional resolution translates into better health recommendations has not been tested in a controlled trial.

Reproducibility Concerns

A 2019 analysis in mSystems (American Society for Microbiology) found that stool microbiome composition in healthy adults showed within-person coefficient of variation of 20 to 40% across samples taken one week apart under identical dietary conditions. [11] This variability raises questions about whether a single baseline test can reliably anchor a multi-month supplement protocol.

Viome Complaints: Patterns and Frequency

Public complaint data across three platforms (BBB, Trustpilot, and Reddit r/Microbiome) shows consistent themes as of Q4 2024.

BBB Complaint Categories

The BBB profile for Viome Life Sciences shows complaints closed in the past three years (exact count fluctuates with resolution rate). The dominant categories are:

1. Billing and collections (auto-ship charges after cancellation request)
2. Service issues (delayed results, sometimes 8 to 12 weeks vs. Promised 2 to 3 weeks)
3. Product or advertising issues (supplement recommendations described as generic despite "personalization" claims)

Viome has generally responded to BBB complaints within the standard 14-day window, and several complaints show resolution through refund or account closure. The pattern of recurrence, however, suggests the auto-ship architecture has not been structurally fixed. [3]

Results Turnaround Time

Viome's website advertises results in 2 to 3 weeks from sample receipt. Consumer complaint data shows that during high-volume periods (January, post-holiday), turnaround has stretched to 8 to 10 weeks. No service-level agreement with financial remedy is published. For comparison, Genova Diagnostics and Doctor's Data both publish formal turnaround-time guarantees on their clinical test menu.

Supplement Quality Concerns

Viome manufactures its precision supplements in-house rather than through NSF International or USP-certified contract manufacturers. NSF and USP third-party certification verifies label accuracy and the absence of contaminants. [12] Without that certification, consumers cannot independently verify that the supplement contains the ingredients at the doses listed. Several Reddit posts have noted that the supplement ingredient lists are non-specific (proprietary blends with undisclosed individual ingredient quantities), which makes independent dose verification impossible.

How Viome Compares to Alternatives at Similar Price Points

For a consumer spending $400 on a gut-related health evaluation, several alternatives exist with different risk-benefit profiles.

Physician-Ordered Clinical Testing

A gastroenterologist or functional medicine physician can order a Genova GI Effects Comprehensive Profile ($400, $500, insurance sometimes covered) or a Doctor's Data Comprehensive Stool Analysis ($300, $450). These panels are CLIA-certified, interpreted by a licensed clinician, and their reference ranges are built on published normative data. The physician is also a licensed professional with liability obligations and a continuing relationship with the patient.

Standard Dietitian Consultation

A registered dietitian (RD) consultation series of four visits costs $200, $400 out-of-pocket in most U.S. Markets, often partially covered by insurance under the Medical Nutrition Therapy benefit. The Academy of Nutrition and Dietetics positions evidence-based medical nutrition therapy as superior to unvalidated precision nutrition tools for most patients. [13]

Doing Nothing (Watchful Waiting)

For individuals without gastrointestinal symptoms, the U.S. Preventive Services Task Force does not recommend routine microbiome screening. [14] The USPSTF's evidence review process requires that screening tests demonstrate net benefit in asymptomatic populations before recommendation. No microbiome screening test currently meets that bar.

Who Might Reasonably Consider Viome

Despite the above limitations, Viome may fit a narrow use case. Individuals who are highly engaged in personal health data, have already addressed modifiable basics (diet quality, sleep, exercise, medication review), want a technically advanced data layer, and understand they are paying for exploratory information rather than clinical guidance can use Viome as one input among many.

The key condition is that the user approaches the supplement recommendations as hypotheses to discuss with a clinician, not as prescriptions. The $399 test fee is defensible as a sophisticated wellness product under those terms. The $1,000+ annual supplement spend on top of that requires a much higher evidence bar that Viome has not yet cleared publicly.

Pricing Trajectory: Where Viome Is Likely Headed

Based on the six-year pricing history, the pattern is a $50 increase every 12 to 18 months on the flagship test, with supplement unit prices rising 8 to 12% annually. Extrapolating conservatively, the Full Body Intelligence Test may reach $449, $499 by 2026.

More significant is the product roadmap. Viome CEO Naveen Jain has publicly described ambitions to expand into cancer early detection (the company published a 2021 paper on oral and throat cancer biomarkers from saliva, N=208, in npj Genomic Medicine). [15] If Viome pursues FDA clearance for a cancer screening test, that pathway involves substantial regulatory investment that would likely be reflected in pricing. A de novo or 510(k) clearance process costs $500,000 to several million dollars before accounting for clinical trial costs. [8]

Subscription bundling will intensify. The trend across DTC health companies is toward annual membership models that lock in a lower per-test price but guarantee recurring revenue. Expect Viome to move toward a $600, $800/year membership that includes one annual test, quarterly supplement adjustments, and app-based coaching, mirroring the model used by companies like InsideTracker and Levels Health.

Concrete Steps Before You Buy

Before committing to a Viome subscription, take these specific actions. First, check the current BBB profile at bbb.org for the most recent complaint volume and resolution rate. Second, read the auto-ship cancellation policy in the checkout terms, not the marketing FAQ, and confirm whether cancellation can be completed online without a phone call. Third, ask your primary care physician or gastroenterologist whether a CLIA-certified clinical stool panel would address your specific concerns at comparable or lower cost. Fourth, if you proceed, set a calendar reminder to cancel before the next supplement renewal date.

For individuals with diagnosed conditions (IBS, IBD, SIBO, celiac disease), a physician-ordered clinical workup remains the standard of care per American College of Gastroenterology guidelines, and a DTC microbiome test does not substitute for that evaluation. [16]